Indexado en

Enlace externo Enlace externo

Licencia y uso

Citaciones

Altmetrics

Análisis de autorías institucional

Martín-Hernández DAutor o CoautorUlecia-Morón CAutor o CoautorPereira M.p.Autor/a o coautor/a de capítulo de libro

Compartir

Monoaminergic system and antidepressants

Publicado en:The Neuroscience of Depression: Features, Diagnosis, and Treatment. 1-2 345-355 - 2021-01-01 1-2(), DOI: https://doi.org/10.1016/B978-0-12-817933-8.00093-1

Autores: Martín-Hernández D; Ulecia-Morón C; Bris ÁG; Caso JR; Pereira MP

Afiliaciones

Resumen

Abstract The standard pharmacological treatment of the major depressive disorder (MDD) is still grounded in a monoaminergic hypothesis of depression. As a consequence, many current antidepressant treatments pursue to heighten monoamine neurotransmissions. Thus, monoamine reuptake inhibitors, as well as monoamine receptor modulators, have been developed as antidepressants and nowadays, they are used widely in clinical practice and they still epitomize the first pharmacological approach to treat mood disorders. In this chapter, the main antidepressants involved in the enhancement of the monoaminergic neurotransmission are being reviewed. Particularly, the chapter focuses on the serotonergic, noradrenergic, and dopaminergic neurotransmissions and on the antidepressant drugs acting on these neurotransmissions. Finally, a short review of the therapeutic implications of less frequent monoamines (i.e., histamine, melatonin, and tryptamine hallucinogens) is also performed at the end of the chapter.

Palabras clave